OncoSil Medical Limited (ASX:OSL) Expands German Hospital Network by 43%
OncoSil Medical (ASX:OSL) expands its presence in Germany with a 43% increase in hospitals authorized to negotiate funding for its innovative OncoSil™ device.
Category: Healthcare
Wellnex Life Limited (ASX:WNX) Obtains TGA Authorisation for New Soft Gel
Wellnex Life (ASX:WNX) secures TGA approval for its Liquid Paracetamol plus Caffeine Soft Gel, expanding its healthcare portfolio and revenue opportunities.
BIOTRON LIMITED (ASX:BIT) Releases Q4 Cash Flow Report
BIOTRON LIMITED (ASX:BIT) announces a net operating cash inflow of $1.095M for Q4, maintaining a strong cash position.
Medlab Clinical Limited (ASX:MDC) Announces Q2 2025 Business Update
Medlab Clinical Limited (ASX:MDC) announces Q2 2025 business update, including AGM plans and ASX removal, with a closing cash balance of $5K.
Micro-X Ltd (ASX:MX1) Reports Q4 Strategic Realignment and Financial Highlights
Micro-X Ltd (ASX:MX1) realigns strategy towards Medical CT, secures $25m ARPA-H funding, and achieves key product milestones in Q4.
Echo IQ Limited (ASX:EIQ) Submits Pre-Submission Meeting Request with US FDA
Echo IQ Limited (ASX:EIQ) submits a pre-submission meeting request with the US FDA for its heart failure solution, EchoSolv HF, progressing towards market entry in H2 2025.
Wellnex Life Limited (ASX:WNX) Q2 FY25 Sales Surge and UK Expansion
Wellnex Life Limited (ASX:WNX) reports a 112% sales increase in 1H FY25 and announces progress in its UK market expansion and dual listing on the London Stock Exchange.
Cann Group Limited (ASX:CAN) Announces Q2 2024 Results
Cann Group Limited (ASX:CAN) announces Q2 2024 results, highlighting improved cash flow, increased production, and plans for future growth.
Emyria Limited (ASX:EMD) Announces Q4 2024 Quarterly Highlights
Emyria Limited (ASX:EMD) reports Q4 2024 achievements in mental health treatments, strategic partnerships, and a successful $2.525M placement.
Clarity Pharmaceuticals (ASX:CU6) Releases Q4 Activity Report
Clarity Pharmaceuticals (ASX:CU6) reports strong Q4 financials, significant trial progress, and entry into the ASX200 index.